Soracent 200 mg (Tablet)

Unit Price: ৳ 150.00 (3 x 10: ৳ 4,500.00)
Strip Price: ৳ 1,500.00

Medicine Details

Category Details
Generic Sorafenib tosylate
Company Incepta pharmaceuticals ltd

Indications

  • Unresectable hepatocellular carcinoma (HCC)
  • Advanced renal cell carcinoma (RCC)

Pharmacology

  • Kinase inhibitor
  • Decreases tumor cell proliferation
  • Inhibits multiple intracellular and cell surface kinases
  • Involved in tumor cell signaling, angiogenesis, and apoptosis

Dosage & Administration

  • Recommended daily dose: 400 mg tablets
  • Taken twice daily without food
  • Treatment duration until patient is no longer clinically benefiting or unacceptable toxicity occurs
  • Management of suspected adverse drug reactions may require temporary interruption and/or dose reduction
  • No dose adjustment based on patient age, gender, or body weight
  • Missed doses: Skip the missed dose and take next dose at regular time. Do not double the dose

Interaction

  • Contraindicated in patients with squamous cell lung cancer when combined with carboplatin and paclitaxel
  • Systemic exposure to UGT1A1 and UGT1A9 substrates may increase
  • Caution recommended when co-administered with Docetaxel, Doxorubicin, Fluorouracil, CYP2B6 and CYP2C8 substrates, and neomycin
  • Inducers of CYP3A4 activity may decrease Soracent concentrations

Contraindications

  • Severe hypersensitivity to Sorafenib or any other component of Sorafenib
  • Contraindicated in patients with squamous cell lung cancer when combined with carboplatin and paclitaxel

Side Effects

  • Serious adverse reactions: cardiac ischemia, infarction, hemorrhage, hypertension, hand-foot skin reaction, rash, gastrointestinal perforation, wound healing complications

Pregnancy & Lactation

  • May cause fetal harm when administered to a pregnant woman
  • Women of childbearing potential advised to avoid becoming pregnant
  • Unknown excretion in human milk

Precautions & Warnings

  • Consider discontinuation in patients developing cardiac ischemia and/or infarction
  • Increased risk of bleeding, hypertension, dermatologic toxicities, and gastrointestinal perforation
  • Monitor patients taking concomitant warfarin regularly
  • Based on clinical judgment, resume therapy following major surgical intervention
  • Use cautiously in combination with various drugs and in hepatic impairment
  • Safety and effectiveness not studied in pediatric patients
  • No dose adjustment required for renal impairment

Use in Special Populations

  • Safety and effectiveness not studied in pediatric patients
  • No differences in safety or efficacy observed between older and younger patients
  • No dose adjustment required for renal impairment
  • AUC may be 23-65% lower in mild to moderate hepatic impairment

Overdose Effects

  • No specific treatment for Soracent overdose
  • Adverse reactions include primarily diarrhea and dermatologic effects

Therapeutic Class

  • Targeted Cancer Therapy

Storage Conditions

  • Store below 30°C at room temperature
  • Dispense in original bottle

Related Brands